Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of rhTPO in Healthy Caucasian Participants
NCT06630494Phase 1Completed
- Sponsor
- 3SBio
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Cytokines & Interferons, Hormones & Growth Factors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thrombopoietin in Thrombocytopenia, sponsored by 3SBio. Primary endpoint: Serum rhTPO concentration at Day 14. Started Oct 2024; status: completed.
02
Drugs
thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT06630494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630494.